Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: Case-control study in patients with multiple myeloma and review of the literature

Leukemia Research

Volumn 31, Issue 11, 2007, Pages 1487-1493

  Musto, Pellegrino ^a   Scalzulli, Potito Rosario ^b   Terruzzi, Elisabetta ^c   Rossini, Fausto ^c   Iacopino, Pasquale ^d   Messina, Giuseppe ^d   Guariglia, Roberto ^a   Pietrantuono, Giuseppe ^a   Villani, Oreste ^a   D'Auria, Fiorella ^a   Falcone, Antonietta ^b   Sanpaolo, Grazia ^b   Valvano, Maria Rosa ^b   Pogliani, Enrico Maria ^c   Morabito, Fortunato ^e  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c AO S Gerardo   (Italy)

^d Centro Unico Regionale Trapianti Cellule Staminali e Terapie Cellulari   (Italy)

^e Unit of Haematology and Stem Cell Transplantation   (Italy)

Author keywords

Autologous transplantation; Filgrastim; G CSF; Myeloma; Neutropenia; Peg filgrastim

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; MELPHALAN; PEGYLATED RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; QUINOLONE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL;

CASE-CONTROL STUDIES; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MULTIPLE MYELOMA; POLYETHYLENE GLYCOLS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 35548933774     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.01.008     Document Type: Article

References (28)

1. Crawford J., Althaus B., Armitage J., et al. National Comprehensive Cancer Network. Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw 3 (2005) 540-555
2. ESMO Guidelines Task Force. ESMO recommendations for the application of hematopoietic growth factors. Ann Oncol 16 (2005) i80-i82
3. Aapro M.S., Cameron D.A., Pettengell R., et al. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453
4. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
5. Hackshaw A., Sweetenham J., and Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphomas?. Br J Cancer 90 (2004) 1302-1305
6. Bohlius J., Reiser M., Schwarzer G., and Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 3 (2004) CD003189
7. Blayney D.W., LeBlanc M.L., Grogan T., et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21 (2003) 2466-2473
8. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004) 634-641
9. Lyman G.H. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther 5 (2005) 1635-1646
10. Biganzoli L., Untch M., Skacel T., and Pico J.L. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 31 (2004) 27-34
11. Roskos L.K., Lum P., Lockbaum P., Schwab G., and Yang B.B. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 46 (2006) 747-757
12. Holmes F.A., Jones S.E., O'Shaughnessy J., et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13 (2002) 903-909
13. Holmes F.A., O'Shaughnessy J.A., Vukelja S., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20 (2002) 727-731
14. Green M.D., et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14 (2003) 29-35
15. Younes A., Fayad L., Romaguera J., Pro B., Goy A., and Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42 (2006) 2976-2981
16. Engert A., Bredenfeld H., Dohner H., et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Haematologica 91 (2006) 546-549
17. Brusamolino E., Rusconi C., Montalbetti L., et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 91 (2006) 496-502
18. Lane S.W., Crawford J., Kenealy M., et al. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leuk Lymphoma 47 (2006) 1813-1817
19. Staber P.B., Holub R., Linkesch W., Schmidt H., and Neumeister P. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 35 (2005) 889-893
20. Jagasia M.H., Greer J.P., Morgan D.S., et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 35 (2005) 1165-1169
21. Vanstraelen G., Frere P., Ngirabacu M.C., Willems E., Fillet G., and Beguin Y. Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 34 (2006) 382-388
22. Martino M., Pratico G., Messina G., et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 77 (2006) 410-415
23. Fenk R., Hieronimus N., Steidl U., et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 34 (2006) 1296-1302
24. Gertz M.A., Lacy M.Q., Dispensieri A., Hayman S.R., and Kumar S.K. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther 6 (2006) 343-436
25. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
26. Durie B.G., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
27. Farese A.M., Yang B.B., Roskos L., Stead R.B., and MacVittie T.J. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplant 32 (2003) 399-404
28. Kuendgen A., Fenk R., Bruns I., et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 38 (2006) 69-70